Given the considerable upregulation of APOE in CRPC and enzalutamide-resistant PCa cell lines, we therefore explored the potential association between APOE expression and resistance to AR-targeted therapy in PCa. The gene discussed is APOE; the disease is posterior cortical atrophy.